SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is facing downward pressure amid community debate over recent earnings, where a revenue miss and concerns regarding the company's AI monetization strategy have overshadowed progress in its cloud infrastructure. While some traders view the stock as undervalued due to its significant cash holdings and potential spin-off catalysts, others remain skeptical, citing persistent weakness in advertising revenue and geopolitical risks associated with Chinese equities.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is trending as traders speculate on upcoming platform upgrades, including mainnet expansions and the anticipation of new liquidity-driven catalysts. While the community maintains a bullish outlook rooted in the protocol's dominance on the Base network, some voices urge patience, citing broader crypto market uncertainty and long-term consolidation.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing volatility driven by anticipation ahead of upcoming earnings and a focus on long-term clinical catalysts, including upcoming data for its DM1 and FSHD programs. While some traders express frustration with the recent price decline and share dilution fears, others point to the stock's valuation relative to its revenue and pipeline potential as a setup for a potential rebound.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors debate the impact of ongoing insider selling and the firm's path to commercial nuclear power, with bulls focusing on long-term AI data center demand and potential catalysts like regulatory updates, while bears point to the lack of revenue and the recent dilution.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trading lower as investors react to a disappointing robotaxi event that lacked clear timelines for mass production, compounded by a new NHTSA investigation into the vehicle's regulatory compliance. Traders are divided on the company's long-term autonomy strategy, with some viewing the Cybercab as a major breakthrough while others express concern over the lack of traditional controls and the slow pace of rollout.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The community is debating the impact of escalating geopolitical tensions in the Middle East and the implementation of retaliatory U.S.-Canada tariffs, with many traders expressing concern that these factors will drive inflation and bond yields higher, potentially triggering a market correction. While some traders remain bullish, pointing to strong institutional momentum in AI-related sectors, others are warning that the current market environment is overextended and susceptible to volatility.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Traders are primarily debating the long-term utility of the project's decentralized infrastructure, with many maintaining a bullish outlook based on developments like the integration of AI-native tools and enterprise use cases. Despite this conviction in the technology, sentiment remains dampened by the asset's significant price decline from historical highs and concerns regarding its tokenomics.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the focus of intense debate, with bulls citing consistent launch successes, long-term growth prospects from the Neutron rocket, and the strategic Iridium acquisition as reasons for optimism. Conversely, bears argue the stock remains overvalued and express skepticism regarding Neutron's development timelines, recent insider selling, and the loss of a major contract to Blue Origin.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased volatility and trader discussion centered on recent volume spikes, with persistent debate between investors who view it as a long-term play on financial infrastructure development and others who characterize the price action as a recurring pump-and-dump scheme. Sentiment remains highly polarized as traders weigh ongoing technical consolidation against skepticism over the project's transparency and historical price performance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as traders react to escalating geopolitical tensions in the Middle East, specifically reports of US military strikes against Iranian targets near the Strait of Hormuz. The conversation reflects a divide between investors anticipating further supply-driven price gains and those betting on a potential market reversal, while the community closely monitors news regarding peace deal speculation and regional infrastructure developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers

Equity

Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries. 

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.

Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?

BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.

Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of -$0.78 up 17.89% YoY
• Reported revenue of $243.68M up 120.39% YoY

BridgeBio reported a net loss of $152.2 million for the quarter, while rising operational costs and inherent risks regarding clinical trial outcomes and market size continue to challenge BridgeBio's financial position.

BridgeBio delivered strong revenue growth for Attruby, advanced three pipeline programs into regulatory review, and strengthened its balance sheet with $1 billion in financing to support BridgeBio's upcoming product launches.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$74.84
Prev Close	$75.41
Open	$74.98
Dividend Yield	0.00%
50-Day Moving Average	$80.60
Beta	1.21
Avg. Volume	2.09M
PE Ratio	-20.97

52-Week High	$93.42
52-Week Low	$48.78
Market Capitalization	$14.63B
EPS (Annual)	-$3.79
Price to Book	-5.81
Revenue Per Employee	$598,421.93

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBIO Fundamentals